A plucked chicken named Horizon Europe According to current information, the European Research Framework Programme "Horizon Europe" is likely to be among the indirect victims of the Corona pandemic: A large part of the funds earmarked … more ➔
Defining the bioprocess is early quality c... As the process determines the product, product characteristics of biological drugs need to be analysed thoroughly right from the beginning of the drug development process. Early understanding of structure-function … more ➔
Quantro: Seed capital by Evotec and Boehri... Germany’s Evotec SE and Boehringer Ingelheim Venture Fund have acquired equal minority stakes in Quantro Therapeutics GmbH, a recently established research-based biotech company based in Vienna. Evotec … more ➔
Sourcing reference productsA biosimilar is a copy version of an approved, original biological medice whose patent protection has expired. The development strategies for biosimilar product and a new biological entity (NBE) differ … more ➔
Targeting coronavirusesViennese APEIRON Biologics AG raised €17.5m to expand ongoing Phase II trials of its coronavirus-specific drug candidate APN01 in Europe to the US and Russia. The recombinant angiotensin-converting … more ➔
COVID-19: Siemens assay outperforms anti...In a Public England Health study, Siemens Healthineers COV2T antibody test was the only assay found to meet both sensitivity and specificity requirements of the MHRA. more ➔
AMR: Big Pharma sets up US$1bn FundAfter leaving the field of antimicrobials 20 years ago because other areas offered better returns, 23 pharma companies and the Novo Foundation have launched a US$1bn fund to fight antimicrobial resistance … more ➔
VarmX bags €32m in Series B roundLeiden-based coagulant developer VarmX NV has closed a €32m Series B financing to push clinical development of VMX-C001, a venom-based modified recombinant Factor X. more ➔
APEIRON Biologics licences MaxCytes elec...Viennese APEIRON Biologics and MaxCyte Inc have entered into licensing agreement covering the use of Maxcytes electroporation platform for APN401 development. more ➔
Immatics launches US$250m Nasdaq-IPOAfter closing the business merging with blank check company Arya Sciences Acquisition Corp, Immatics Inc has been listed on Nasdaq. more ➔
